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I 
INTRODUCTION 
Science is built on the sharing of information.  Scientists generate 
knowledge to explain the workings of the natural world, building on the 
information produced and shared by other scientists.  Some scientists see this 
construction in moral or ethical terms;1 according to Albert Einstein, for 
example, “The right to search for truth implies also a duty: one must not 
conceal any part of what one has recognized to be true.”2 
Science flourishes best in conditions of the open and public exchange of 
ideas, methods, findings, and interpretations.  Openness facilitates vetting new 
findings and new theories through continued study and analysis.  The open 
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 1. See, e.g., A Duty to Publish, 4 NATURE MED. 1089, 1089 (1998) (listing recent instances in 
which drug companies tried to suppress the unfavorable results of studies they helped to fund, but the 
researchers, “acting in the interests of the public,” resisted the pressure and published their findings). 
 2. Id. 
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exchange of ideas is valued not only because it facilitates the advancement of 
science, but also because it is concordant with the ideals of a democratic society. 
The principles and practice of open science can come into conflict with 
individual or corporate actions intended to limit public access to information, or 
with government laws and policies that restrict access to results and ideas.  
Sometimes these restrictions are needed to preserve important values, such as 
individual privacy, or to further certain policy objectives, such as protecting 
national security or the economic benefits derived from innovation.  However, 
there are also potential costs to restricting certain kinds of information; for 
example, when such suppression limits public knowledge about health risks, it 
can prevent people and their government from protecting public health. 
The best known and most tragic examples of data sequestration contributing 
to public health disasters are tobacco and asbestos.  The tobacco industry 
developed extensive structures and policies to hide scientific studies whose 
results were detrimental to the industry’s health.3  The confidentiality that 
accompanies the attorney–client relationship was a particularly important tool 
to sequester data on the powerful, terrible effects of cigarette smoke on the 
health of smokers.4  Similarly, an untold portion of the worldwide epidemic of 
asbestos-related disease—currently estimated at 100,000 deaths each year—
might have been prevented had the manufacturers of asbestos products not 
systematically hidden the results of inhalation studies linking asbestos with lung 
cancer, performed in the 1940s.5 
Of course, the concealment of scientific evidence has not been limited to the 
tobacco and asbestos contexts, and less well-known episodes of data 
sequestration have occurred in relation to several industrial chemicals.6  More 
recently, instances in which drug manufacturers withheld study results 
unfavorable to their product but clearly important in terms of patient treatment7 
 
 3. See generally STANTON A. GLANZ ET AL., THE CIGARETTE PAPERS 235–87 (1996). 
 4. See, e.g., Lisa Bero et al., Lawyer Control of the Tobacco Industry’s External Research 
Program: The Brown and Williamson Documents, 274 JAMA 241-47 (1995); Stanton A Glantz et al., 
Looking Through a Keyhole at the Tobacco Industry: The Brown and Williamson Documents, 274 
JAMA 219–24 (1995); Peter Hanauer et al., Lawyer Control of Internal Scientific Research to Protect 
Against Products Liability Lawsuits: The Brown and Williamson Documents, 274 JAMA 234–40 (1995).  
See also Glanz, supra note 3, at 235–87. 
 5. Press Release, International Labour Organization (ILO) & World Health Organization 
(WHO), Number of Work Related Accidents and Illnesses Continues to Increase: ILO and WHO Join 
in Call for Prevention Strategies (Apr. 28, 2005), available at 
http://www.ilo.org/public/english/bureau/inf/pr/2005/21.htm.  See also BARRY I. CASTLEMAN, 
ASBESTOS: MEDICAL AND LEGAL ASPECTS 41–132 (2005). 
 6. See Wendy Wagner & David Michaels, Equal Treatment for Regulatory Science: Extending the 
Controls Governing the Quality of Public Research to Private Research, 30 AM. J.L. & MED. 119, 121–28 
(2004). 
 7. See, e.g., D. Blumenthal et al., Withholding Research Results in Academic Life Science: 
Evidence from a National Survey of Faculty, 277 JAMA 1224–28 (1997); B. Psaty & D. Rennie, 
Stopping Medical Research to Save Money: A Broken Pact with Researchers and Patients, 289 JAMA 
2128, 2128–31 (2003); D. Rennie, Thyroid Storm, 277 JAMA 1238–43 (1997); S.A. Rosenberg, Secrecy 
in Medical Research, 334 N. ENG. J. MED. 392, 392–94 (1996). 
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have been the impetus to major changes in the registration and reporting of 
clinical trials in biomedical literature. 
Concerned about these issues, the Planning Committee of the Project on 
Scientific Knowledge and Public Policy (SKAPP)8 convened a symposium to 
explore the scientific and social consequences of failure to disclose scientific 
knowledge.  The symposium placed special emphasis on the tension between 
the imperative to protect public health and safety and provisions restricting 
access to documents whose publication or dissemination might result in 
financial harm.  The second Coronado Conference,9 Sequestered Science: The 
Consequences of Undisclosed Knowledge (Coronado II), brought leading 
scholars and practitioners from the fields of philosophy of science, law, ethics, 
business, and public health to New York City on October 14–15, 2004, to 
discuss these issues.  This issue of Law and Contemporary Problems includes 
papers presented at Coronado II and others solicited for inclusion in this 
publication. 
Science has the connotation of openness; the phrase “sequestered science” 
is intentionally discordant.  An objective of this collection of articles is to 
examine that discordance.  Several articles discuss the tradeoffs involved in the 
decision to sequester science.  Who participates in weighing cost against 
benefits?  Which and whose values are considered?  Is this process of deciding 
what is to be sequestered open to public scrutiny—or is it likewise sequestered?  
A further objective is to explore incentives, such as laws and regulations, to 
enhance or limit the production of knowledge.10 
The U.S. regulatory system faces a difficult challenge: safeguards are 
inadequate to ensure appropriate access to the results of scientific studies 
needed to protect public health and safety and the environment.  Nevertheless, 
 
 8. SKAPP, based at the George Washington University School of Public Health, engages 
scientists in examinations of the nature of science and how it is used and misused in government 
decisionmaking and legal proceedings.  Through empirical research, discussions among scholars, and 
publications, SKAPP aims to enhance understanding of how knowledge is generated and interpreted.  
Major funding for SKAPP, and support for this symposium, is provided by the Common Benefit Trust, 
a fund established pursuant to a court order in the Silicone Gel Breast Implant Products Liability 
litigation.  The funding is unrestricted; we do not provide our funders the opportunity to review or 
approve our activities.  For more information, see the SKAPP website at 
http://www.DefendingScience.org. 
 9. The first Coronado Conference hosted by SKAPP, Scientific Evidence and Public Policy, was 
held in March 2003.  At the conference, the distinguished group of participants examined the use and 
misuse of scientific evidence in public policy and the implications of the 1993 Supreme Court decision 
in Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579 (1993).  The participants focused on how 
these issues are worked out in the legal and regulatory arena, with topics that included the meaning of 
causation, how scientists reach judgments, and whether there is a scientific method.  Additional 
information is available at http://www.DefendingScience.org.  In addition, the papers and 
commentaries presented at the 2003 Coronado Conference have been published in a special 
supplement to the American Journal of Public Health and are available for downloading from the 
SKAPP website.  See 95 AM. J. PUB. HEALTH 4 (2005). 
 10. In the public health arena, the Toxic Substances Control Act, 15 U.S.C. §§ 2601–2671 (1976), 
and the Pure Food and Drug Act, Pub. L. No. 59-384, 34 Stat. § 768 (1906) (codified as amended at 21 
U.S.C. 1-15 (1934)), are good examples of these types of legal incentives to create knowledge. 
01__FOREWORD.DOC 10/4/2006  9:00 AM 
4 LAW AND CONTEMPORARY PROBLEMS [Vol. 69:1 
as several authors in this issue note, excessive transparency can have significant 
negative consequences to society. 
In the early part of this decade, the nation grappled with a different set of 
issues relating to data integrity and transparency, namely, questionable 
accounting and reporting practices led to the bankruptcies of Enron and 
WorldCom, as well as the demise of the “Big Five” accounting firm Arthur 
Andersen.  The economic and social impact of the scandals was substantial, 
including a huge reduction of shareholder assets and the disappearance or 
substantial reduction of the pensions of thousands of workers.  In response, the 
U.S. Congress enacted the American Competitiveness and Corporate 
Accountability Act of 2002, commonly known as the Sarbanes-Oxley Act.11 
Based on the findings and conclusions of the authors in this issue, this article 
ends with a call for another Sarbanes-Oxley initiative—one for science.  
Although the needs of science and accounting are quite different, the Sarbanes-
Oxley Act inspires a need for legislation that would safeguard the integrity and 
transparency of scientific data vital to protecting the public, while recognizing 
the valid need for limited data sequestration in certain circumstances. 
II 
THE SEQUESTERED SCIENCE SYMPOSIUM PAPERS 
The contours of the policy debate over data sequestration are lyrically 
described by Sheila Jasanoff in this issue’s opening essay.12  Jasanoff, one of the 
country’s most insightful and important thinkers on the use of science in public 
policy,13 explains that “[o]penness and transparency in science, then, cannot be 
treated as absolute goods.  Rather, the degree of openness is context-specific 
and needs to be traded off against other important social values.  The problem 
for contemporary law and policy is to develop principled approaches to 
maintaining the desired balance.”14 
Jasanoff looks at issues of transparency in both regulation and litigation.  In 
what she describes as “public, or policy-relevant, science,”15 she rejects the 
relatively superficial question of whether information should be transparent, 
recognizing the greater inquiry for whom such science should be transparent 
and for what purpose.  As she notes, “Openness is a treasured attribute of 
science, but like most good things, even scientific openness has to be 
 
 11. Pub. L. No. 107-204, 116 Stat. 745 (2002) (codified as amended in scattered sections of 15 
U.S.C.). 
 12. Sheila Jasanoff, Transparency in Public Science: Purposes, Reasons, Limits, 69 LAW & 
CONTEMP. PROBS. 21 (Summer 2006). 
 13. See, e.g., SHEILA JASANOFF, THE FIFTH BRANCH: SCIENCE ADVISORS AS POLICYMAKERS 
(1990); SHEILA JASANOFF, SCIENCE AT THE BAR: LAW, SCIENCE AND TECHNOLOGY IN AMERICA 
(1995).  Jasanoff is the Pforzheimer Professor of Science and Technology Studies at the John F. Kennedy 
School of Government of Harvard University. 
 14. Jasanoff, supra note 12, at 20. 
 15. Id. at 29. 
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purposefully cultivated and judiciously deployed in order to serve its intended 
functions well.”16 
Jasanoff then succeeds in refocusing the question at hand, from how to 
ensure the disclosure of useful information to how to transform the judicial 
system so that it contributes to the generation of knowledge for public good.  
She argues that “litigation is an indispensable aid to knowledge production,” a 
fact that should lead to the design of “procedures aimed at increased 
transparency, such as enforced negotiation between parties,” and that “some 
forms of external review, could be devised to improve the quality and reliability 
of the science that lawsuits help generate.”17 
The tradeoffs between data sequestration and disclosure discussed by Jasanoff 
are particularly acute in the production and marketing of drugs.  The choices made 
in this arena have substantial implications, both for public health and for the 
financial health of the corporations involved.  Three papers in this issue address 
these choices.18 
First, noted philosopher of science Susan Haack19 recounts the tale of the 
drug Remune, in which the drug’s manufacturer hired scientists to conduct a 
clinical trial but subsequently blocked the scientists’ efforts to reveal that the drug 
was ineffective in slowing the progression of HIV-related disease.20  As recounted 
by Haack, the manufacturer encouraged investors to believe Remune was 
effective, at the same time litigating against the scientists for violating an 
agreement to keep certain information confidential—information that would have 
shown the drug actually to be ineffective.21  Although for a few years the 
manufacturer was able to maintain the illusion that Remune was effective, the 
unfavorable findings from the clinical trial eventually came to light and forced the 
company to abandon the drug.22  Nevertheless, over that period, the company gave 
out false information—along with false hope—to AIDS patients and investors 
alike. 
 
 16. Id. at 40.  Jasanoff further explains reasons for and methods to ensure such safeguards: 
[S]ome common pathologies of science-based decisionmaking [are] imperfect accountability, 
asymmetric standards, and excessive transparency. . . . All three affect the production of 
reliable scientific knowledge, but all reflect at bottom procedural deficiencies: withholding 
access from, or in some cases granting it to, the wrong people, at the wrong times, for the 
wrong purposes. 
Id. 
 17. Id. at 42. 
 18. Susan Haack, Scientific Secrecy and “Spin”: The Sad, Sleazy Saga of the Trials of Remune, 69 
LAW & CONTEMP. PROBS. 47 (Summer 2006); Scott M. Lassman, Transparency and Innuendo: An 
Alternative to Reactive Over-Disclosure, 69 LAW & CONTEMP. PROBS. 69 (Summer 2006); Peter Lurie & 
Allison Zieve, Sometimes the Silence Can Be Like the Thunder: Access to Pharmaceutical Data at FDA, 
69 LAW & CONTEMP. PROBS. 85 (Summer 2006). 
 19. Haack was included in PETER J. KING, 100 PHILOSOPHERS: THE LIFE AND WORK OF THE 
WORLD’S GREATEST THINKERS 180 (2004).  She is the Cooper Senior Scholar in Arts and Science and 
Professor of Philosophy and Law at the University of Miami. 
 20. Haack, supra note 18, at 52–60. 
 21. Id. 
 22. Id. at 59. 
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Haack uses this case study to illustrate “how scientific inquiry can be 
hampered or perverted by pressure to transform it into boosterism for a 
product (or a policy).”23  Haack concludes the “scientific ethos” is threatened 
when science becomes entangled with commercial interests and these types of 
relationships have significant consequences for the advancement of science.24 
Many commentators have noted the recent, rapid demise of the barriers 
between commerce and science, particularly in medicine.25  Aided by the 
passage of the Bayh-Dole Act,26 universities are forming lucrative collaborations 
with private corporations.27  In the medical sphere, much of this cooperation has 
focused on the development and testing of new drugs.  Remune was only one of 
several recent episodes of data sequestration in which the sponsors of research 
used their financial control to the detriment of public health.28  In response to 
this trend, a group of editors of the world’s leading biomedical journals declared 
they would no longer publish articles based on studies conducted under 
contracts in which the investigators did not have the unfettered right to publish 
their findings.29  They asserted that such contractual arrangements 
not only erode the fabric of intellectual inquiry that has fostered so much high-quality 
clinical research but also make medical journals party to potential misrepresentation, 
since the published manuscript may not reveal the extent to which the authors were 
powerless to control the conduct of a study that bears their names.30 
Although the opprobrium of these editors undoubtedly focused the attention 
of the biomedical community on the sequestration of unfavorable clinical trial 
results, the intervention of New York Attorney General Eliot Spitzer has 
fundamentally altered the debate.  In June 2004, Spitzer filed suit against 
GlaxoSmithKline (GSK), charging that the pharmaceutical company concealed 
unfavorable scientific studies on the efficacy and safety for children of the 
antidepressant Paxil.31  Specifically, Spitzer alleged that GSK had withheld data 
that adolescents taking Paxil were at increased risk of suicidal thoughts and 
acts32—meaning the sequestration of this information might have prevented 
 
 23. Id. at 60. 
 24. See id. (noting that this pressure “damages the fragile social mechanisms that sustain the scientific 
ethos of honest investigation and encourage free exchange of ideas and information”). 
 25. See id. at 47 (referencing the works of several commentators that discuss the potential 
problems of commercially sponsored scientific research). 
 26. 35 U.S.C. §§ 200–212 (1980).  This legislation allows small businesses and universities to elect 
ownership of patents over inventions created with federal funding and to become directly involved in 
the process of commercialization; it has the “policy and objective” of “promot[ing] collaboration 
between commercial concerns and nonprofit organizations, including universities.”  Id. at § 200. 
 27. SHELDON KRIMSKY, SCIENCE IN THE PRIVATE INTEREST: HAS THE LURE OF PROFITS 
CORRUPTED THE VIRTUE OF BIOMEDICAL RESEARCH? (2003). 
 28. See Haack, supra note 18, at 60–61. 
 29. Frank Davidoff et al., Sponsorship, Authorship and Accountability, 286 JAMA 1232, 1233 
(2001).  The statement was jointly issued by the editors of thirteen leading journals. 
 30. Id. 
 31. See Complaint, State v. GlaxoSmithKline (N.Y. Sup. Ct. June 2, 2004), available at 
http://files.findlaw.com/news.findlaw.com/cnn/docs/glaxo/nyagglaxo60204cmp.pdf. 
 32. See, e.g., Eliot Marshall, Buried Data Can Be Hazardous to a Company’s Health, 304 SCIENCE 
1576, 1576–77 (2004); Editorial, Is GSK guilty of fraud?, 363 LANCET 1919, 1919 (2004). 
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doctors treating children with mood disorders from considering all of the 
relevant scientific information necessary to make informed decisions with 
patients and their families.  Less than a month after the suit was filed, GSK 
announced it would release the clinical data on Paxil’s safety and effectiveness;33 
later that year, another pharmaceutical manufacturer agreed to create a public 
registry of clinical trials data for its antidepressant medications.34 
These scandals, accompanied by empirical research showing they were not 
isolated instances but symptomatic of a larger problem,35 have contributed to a 
change in the relationship between the pharmaceutical industry and the editors 
of the medical journals in which clinical trial results are published.  Several 
physicians who have served as editors of the most important biomedical 
journals have written scathing critiques of drug company practices, focusing 
particularly on the publication and interpretation of clinical trial results.36  In 
fact, the culture of drug testing has changed sufficiently that it is now widely 
recognized that pharmaceutical manufacturers have an obligation to report the 
existence and results of all clinical trials,37 although this is often not done 
satisfactorily.38 
 
 33. See Press Release, Office of New York State Attorney General Eliot Spitzer, Statement 
Regarding Decision by GlaxoSmithKline to Post Summaries of Clinical Trial Result (June 18, 2004)(on 
file with author).  Spitzer stated that it was “unacceptable for companies like GSK to divulge favorable 
results while hiding negative data when the health of patients is at stake.”  Id. 
 34. Press Release, Office of New York State Attorney General Eliot Spitzer, Forest Labs to 
Establish Clinical Trials Registry (Sept. 7, 2004)(on file with author). 
 35. See An-Wen Chan et al., Empirical Evidence for Selective Reporting of Outcomes in 
Randomized Trials: Comparison of Protocols to Published Articles. 291 JAMA 2457, 2457–65 (2004) 
(“The reporting of trial outcomes is not only frequently incomplete but also biased and inconsistent 
with protocols.”).  This research arose out of the uproar around incomplete reporting of clinical trial 
results, which led investigators to study the conduct and reporting of research itself.  One of the 
challenges in conducting this research was to identify either a representative or complete sample of 
clinical trials that have been initiated in order to see when and how the results were provided to the 
public.  An ingenious group of European researchers was able to take this on, utilizing the records of 
the Scientific-Ethical Committees for Copenhagen and Frederiksberg, Denmark, the Institutional 
Review Board (IRB) through which all clinical trials conducted in that region must be registered and 
approved.  There were 102 trials approved in 1994–1995 that eventually were completed and published, 
resulting in 122 journal articles.  The researchers found that half the efficacy outcomes and sixty-five 
percent of harm outcomes were incompletely reported.  More than sixty percent of the trials had at 
least one primary outcome that was changed, introduced after the protocol was approved, or omitted.  
Eighty-six percent of survey responders (forty-two out of forty-nine) denied the existence of 
unreported outcomes despite clear evidence to the contrary.  Id. at 2457. 
 36. See, e.g., MARCIA ANGELL, THE TRUTH ABOUT DRUG COMPANIES (2004); JEROME P. 
KASSIRER, ON THE TAKE: HOW MEDICINE’S COMPLICITY WITH BIG BUSINESS CAN ENDANGER 
YOUR HEALTH (2005); Richard Smith, Medical Journals are an Extension of the Marketing Arm of 
Pharmaceutical Companies, 2 PUB. LIBR. SCI. MED. 364, 364–66 (2005). 
 37. See C. DeAngelis et al., Is this Clinical Trial Fully Registered?  A Statement from the 
International Committee of Medical Journal Editors, 352 N. ENG. J. MED. 2436, 2436–38 (2005) “In 
September 2004, the members of the International Committee of Medical Journal Editors (ICMJE) 
published a joint editorial aimed at promoting registration of all clinical trials.”  The members of the 
ICMJE will consider a trial for publication only if it is registered for the purpose of providing a 
“comprehensive, publicly available database of clinical trials.” 
 38. See C. Rowland, Drug Firms Lagging on Openness, BOSTON GLOBE, Jan. 9, 2005, at A1.  
Despite increased levels of voluntary disclosure by drug firms, “[a] Globe review of websites indicates 
that the voluntary approach has produced limited disclosures thus far.”  Id. 
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Another aspect of the movement for increased disclosure or transparency is 
the Food and Drug Administration’s (FDA) new “Drug Safety Initiative,” which 
seeks to increase the access of patients, health care providers, and consumers to 
drug safety information.39  A component of this initiative would be a proposed 
“Drug Watch” website, intended to enable FDA to “communicate emerging 
safety information to the public” while it is under evaluation by the agency.40 
Scott Lassman asserts in his paper that although this FDA goal of “prompt 
communication of important and useful safety information about drug products 
to physicians and patients” is a laudable one, the FDA’s planned website could 
actually have an adverse impact on public health.41  Specifically, Lassman 
projects that the use of the website “would (1) disseminate unverified and 
potentially misleading safety information; (2) prompt physicians and patients to 
make healthcare decisions based on little more than scientific innuendo; and, 
(3) undercut well-established methods of risk communication, such as the 
approved drug label.”42  Lassman’s preference would be to use the website “as 
part of an accelerated labeling revision process, which would provide valid and 
useful safety information in a more timely manner.”43 
Although much of Lassman’s paper focuses on the Pharmaceutical Research 
and Manufacturers of America’s (PhRMA) detailed concerns about this current 
FDA proposal,44 it also raises fundamental issues that transcend the specifics of 
the proposed Drug Watch website.  At its heart, Lassman’s paper addresses a 
common dispute in public health: when and how the public should be informed 
about possible health risks.  Proponents of a broad “right to know” argue that 
information should not be kept from the public, even if its implications are not 
yet clear.45  They argue that freedom of choice is hampered if relevant (if 
imperfect) information is withheld.46  Finally, even if dissemination of research 
results should be limited in some cases, they question whether manufacturers of 
 
 39. Press Release, Food and Drug Administration, New Drug Safety Initiative (May 5, 2005), 
available at http://www.fda.gov/cder/drugSafety.htm. 
 40. Draft Guidance for the Industry on the Food and Drug Administration’s “Drug Watch” for 
Emerging Drug Safety Information; Availability, 70 Fed. Reg. 24,606 (May 10, 2005). 
 41. Lassman, supra note 18, at 69.  Lassman is Assistant General Counsel of the Pharmaceutical 
Research and Manufacturers of America (PhRMA). 
 42. Id. 
 43. Id. 
 44. See also Scott Lassman & Alan Goldhammer, RE: Docket No. 2005D-0062, FDA Request for 
Comments on the Draft Guidance entitled, “FDA’s ‘Drug Watch’ for Emerging Drug Safety 
Information,” 70 Fed. Reg. 24,606 (May 10, 2005), (PhrMA), Aug. 8, 2005, available at 
http://www.fda.gov/ohrms/dockets/dockets/05d0062/05d-0062-c000013-vol1.pdf. 
 45. See John S. Applegate, The Perils of Unreasonable Risk: Information, Regulatory Policy, and 
Toxic Substances Control, 91 COLUM. L. REV. 261 (1991); Mary Lyndon, Information Economics and 
Chemical Toxicity: Designing Laws to Produce and Use Data, 87 MICH. L. REV. 1795 (1989); David 
Roe, Barking up the Right Tree: Recent Progress in Focusing the Toxics Issue, 13 COLUM. J. ENVTL. L. 
275 (1988). 
 46. Id. 
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potentially harmful substances should be making decisions about when risk 
information is reliable enough to release to the public.47 
In this context, Lassman’s paper raises the issue of the control of 
dissemination of vital information about product safety.  As Lassman notes, the 
primary and current mechanism for communicating about risks associated with 
taking a particular pharmaceutical is the label.48  This label generally refers not 
to something affixed to the package but to the lengthy enclosure provided to 
purchasers and published in advertisements extolling the efficacy of a medicine.  
Currently, drug labels are often the product of extensive negotiation between 
FDA and a drug’s manufacturer.49  Opposing FDA’s efforts to establish a 
mechanism independent of the drug manufacturers to communicate data on 
drug safety, Lassman’s paper argues for maintaining the role of the 
manufacturer in interpreting data on risks associated with drugs and in shaping 
how this information is conveyed to physicians and consumers.50 
The Public Citizen’s Health Research Group (HRG) has been closely 
monitoring the new FDA drug approval process for several decades, starting long 
before the recent, highly publicized episodes of data sequestration cited above.51  
The HRG provides the public with an independent appraisal of the data that 
manufacturers provide to FDA, then continues to examine the safety and efficacy 
of drugs after they have been approved by the agency.52  According to the HRG, 
the organization has filed twenty-seven petitions since 1971 requesting FDA to 
withdraw drugs from the market, contending that the drugs were not efficacious or 
that their risks outweighed their benefits.53  For the most part, FDA eventually 
 
 47. Id. 
 48. Lassman, supra note 18, at 76–78. 
 49. See Gardiner Harris, F.D.A. Official Admits ‘Lapses’ on Vioxx, N.Y. TIMES, Mar. 2, 2005, at 
A15 (quoting an FDA official that the agency “[doesn’t] have the authority to tell a company, ‘this is 
how your label has to look’. . . . We have to negotiate with the company the specific language of how 
things should be worked, the placement, those kinds of things, after talking to them.”).  This statement 
came in testimony at a 2004 U.S. Senate hearing investigating FDA’s approval of Vioxx (rofecoxib), a 
situation that illustrates the public health consequences of FDA’s inability to specify the content of 
warning labels.  It took more than a year for information about the cardiovascular risks of Vioxx 
identified by an FDA advisory panel to be added to the drug’s label.  According to at least one account, 
FDA and Merck “battled over the label.”  Anna Wilde Mathews, Did FDA Staff Minimize Vioxx’s Red 
Flags?, WALL ST. J., Nov. 10, 2004, at B1.  See also Anna Wilde Mathews & Barbara Martinez, E-mails 
Suggest Merck Knew Vioxx’s Dangers at Early Stage, WALL ST. J., Nov. 1, 2004, at A1. 
 50. Notwithstanding Lassman’s conclusions, the recent history of the marketing and withdrawal of 
Vioxx (rofecoxib), discussed infra in Part III, is an illustration of the problems associated with that type 
of reliance on the interpretation of data by scientists with financial conflicts of interest. 
 51. For more information about Public Citizen’s Health Research Group, see 
http://www.citizen.org/hrg. 
 52. Id. 
 53. Sidney Wolfe, Is the FDA Adequately Assuring Drug Safety?, Power Point Presentation at the 
Food and Drug Law Institute (FDLI) 48th Annual Conference, Preparing for the Next Century of Drug 
Regulation, April 7, 2005. 
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agreed with the HRG’s independent assessments, indicating that the HRG’s 
interventions have made a significant contribution to public health.54 
The paper by Peter Lurie and Allison Zieve is an analytical examination of 
the HRG’s attempts to monitor the workings of FDA’s drug approval process 
through disclosure mechanisms provided by two important sunshine statutes:55  
the Freedom of Information Act (FOIA)56 and the Federal Advisory 
Committee Act (FACA).57  New drug applications are reviewed by FDA advisory 
committees, whose recommendations are generally accepted by the agency.58  As a 
result of a successful HRG lawsuit, FDA initiated a policy to place the materials 
already provided to advisory committee members on the FDA website twenty-
four hours prior to each advisory committee meeting,59 enabling members of the 
public to have adequate information to participate meaningfully in the meeting. 
Lurie and Zieve also describe how, despite this success in fighting for 
greater transparency, FDA has withheld other information that the HRG 
believes would be beneficial to public health.  Lurie and Zieve conclude 
[a]t each step of the drug approval process, a variety of documents of potential 
relevance to the public health are generated.  To date, numerous contentious legal 
battles have been waged to obtain access to information generated during various 
stages in this process, with FDA typically weighing in alongside the manufacturer and 
favoring nondisclosure.  Obstacles to the release of information at each of these stages 
must be addressed if optimal transparency in the drug approval process is to be 
assured.60 
FOIA and FACA, two of the basic tools used by the public to monitor the 
activities of the government, are also a major focus of the paper by Sidney A. 
Shapiro and Rena I. Steinzor.61  These authors assert that the administration of 
President George W. Bush has invoked the “war on terrorism” to justify 
withholding information that was routinely disclosed by past Presidents;62 
moreover, they argue that recent “[j]udicial interpretations and executive 
 
 54. Of the drugs implicated in the twenty-seven petitions, eighteen (sixty-seven percent) were 
eventually withdrawn from the market, and the use of an additional four (fifteen percent) has been severely 
limited.  Id. 
 55. Lurie & Zieve, supra note 18, at 87–95.  Lurie is a physician and Deputy Director of HRG; 
Zieve is Senior Attorney of HRG. 
 56. 5 U.S.C. § 552 (2000).  FOIA requires that, upon request by any person, an agency must 
disclose documents that do not fall into one of nine specific exemptions from disclosure.  Id. 
 57. 5 U.S.C. App. II §§ 1–15 (2000).  Federal advisory committees constituted under FACA are 
subject to disclosure requirements, including an advance notice of upcoming meetings and 
opportunities for public attendance and input.  Id. at § 10. 
 58. Kenneth I. Kaitin, et al., FDA Advisory Committees and the New Drug Approval Process, 29 J. 
CLINICAL PHARMACOLOGY 886 (1989). 
 59. Lurie & Zieve, supra note 18, at 90. 
 60. Id. at 93. 
 61. Sidney A. Shapiro & Rena I. Steinzor, The People’s Agent: Executive Branch Secrecy and 
Accountability in an Age of Terrorism, 69 LAW & CONTEMP. PROBS. 99, (Summer 2006).  Shapiro is 
Distinguished Chair in Law at Wake Forest University, and Steinzor is Professor of Law at University 
of Maryland School of Law.  Both authors are among the founders of the Center for Progressive 
Reform, a nonprofit research and educational organization that focuses on the government’s role in 
protecting health, safety, and the environment. 
 62. Id. at 97. 
01__FOREWORD.DOC 10/4/2006  9:00 AM 
Summer 2006] FOREWORD 11 
branch hostility have narrowed the application of both FOIA and FACA.”63  
The authors further describe the Critical Infrastructure Information Act 
(CIIA), enacted as part of the Homeland Security Act of 2002,64 and its 
implications on the public’s ability to learn more about the functioning of the 
U.S. government. 
Shapiro and Steinzor call on Congress to reverse the judicial interpretations 
that have weakened FOIA and FACA and to restore the open government 
requirements that Congress originally intended in these sunshine laws.  Echoing 
other papers in this collection, Shapiro and Steinzor recognize that “wise 
policymaking requires a balancing of competing interests in secrecy and 
openness.”65  It is of particular importance, therefore, that “such decisions . . . be 
made by dispassionate and authoritative officials who have no personal stake in 
whether the information is ultimately disclosed.”66 
These calls for developing principled approaches to maintaining the desired 
balance between openness and sequestration are underscored by Daniel J. 
Givelber and Anthony Robbins, who examine the potential impact on public 
health of information uncovered in litigation.67  Givelber and Robbins call 
attention to “[p]rotective orders and other secrecy agreements [that] have 
shielded many patterns of injury and disease associated with dozens of 
materials, products, and processes.”68  While recognizing there are valid reasons 
for secrecy, the authors ask, “Should courts, as public entities devoted to 
dispute resolution, tolerate, endorse, or protect secrecy when the sequestered 
information might help protect the public health?”69 
Not all courts uniformly protect the ability of plaintiff and defense counsels 
to sequester information whose disclosure may benefit the public.70  For 
 
 63. Id. at 99.  Evidently this antipathy to open-government statutes has deep roots.  Two prominent 
members of the Bush Administration were opposed to legislation expanding FOIA when it was passed 
by Congress in 1977; at that time, current Secretary of Defense Donald Rumsfeld was Chief of Staff to 
President Gerald Ford, and now-Vice President Richard Cheney was his deputy.  See id. at 126. 
(“Presumably acting under [Rumsfeld’s and Cheney’s] advice, President Ford vetoed amendments 
expanding the FOIA, only to have his veto overridden by Congress.”). 
 64. 6 U.S.C. § 131 (2002). 
 65. Shapiro & Steinzor, supra note 61, at 99. 
 66. Id. 
 67. Daniel J. Givelber & Anthony Robbins, Public Health vs. Court-sponsored Secrecy, 69 LAW & 
CONTEMP. PROBS. 131 (Summer 2006).  Givelber’s and Robbins’s work is itself a collaboration of law 
and public health; Givelber, Professor of Law at Northeastern School of Law, served as that school’s 
dean from 1984 until 1993.  Robbins is a national figure in public health, having directed the Vermont 
State Health Department, the Colorado Department of Health, the U.S. National Institute for 
Occupational Safety and Health, and the U.S. National Vaccine Program.  Currently he is Professor of 
Public Health at Tufts University School of Medicine, and a member of the SKAPP planning 
committee. 
 68. Id. at 131. 
 69. Id. at 129. 
 70. See Arthur R. Miller, Confidentiality, Protective Orders, and Public Access to the Courts, 105 
HARV. L. REV. 427, 490–501 (1991).  One important rationale often made for confidentiality 
agreements is efficiency; there is debate over a feared “chilling” impact of forced transparency on the 
willingness of parties to settle cases before trial.  Some years ago, Arthur R. Miller wrote that 
restrictions on the use of mechanisms that sequester information uncovered in the course of litigation 
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example, judges in toxic tort cases must consider this issue specifically in 
approving secrecy agreements that encourage settlement and docket clearing.71  
Some have issued rules “disfavoring court-ordered secrecy in cases affecting 
public safety;”72 others have suggested that “[p]erhaps existing rules of civil 
procedures and ethics should be altered to encourage attorneys as well as 
judges to more carefully consider the interests of scientists and the general 
public interest in publication of private information when resolving legal 
disputes.”73 
Givelber and Robbins contribute to this dialogue with an intriguing 
proposal to expand the nexus beyond the behavior of judges and attorneys.  In 
cases in which the defendant has previously used confidentiality agreements to 
sequester information about products or practices implicated in subsequent 
injuries, the authors recommend allowing a jury to decide if the defendant’s 
involvement in a secrecy agreement influences the defendant’s punitive 
liability.74 
While Givelber and Robbins focus on secrecy in court proceedings, James 
W. Conrad Jr. describes the requirements for transparency in regulation of 
chemicals and contends that economic considerations do not result in 
concealment of health or safety data.75  He maintains that federal statutes 
requiring disclosure—such as the Toxic Substances Control Act (TSCA),76 the 
Federal Insecticide, Fungicide and Rodenticide Act (FIFRA),77 and Sarbanes-
Oxley,78 as well as legal disincentives to concealment, including fear of potential 
 
would discourage settlements and result in further burdening the court system.  Id.  These restrictions 
are unnecessary, because judges currently have the discretion to ensure that information important to 
public welfare is provided to appropriate government agencies.  Id.  In response, James E. Rooks Jr. 
has recently pointed out that there is no empirical evidence of an increase in trial rates in jurisdictions 
imposing limits on secrecy in litigation.  James E. Rooks Jr., Settlements and Secrets: Is the Sunshine 
Chilly?, 55 S.C. L. REV. 859, 870–75 (2004). 
 71. See Jack B. Weinstein, Symposium: Panel II: Secrecy and the Civil Justice System, Secrecy in 
Civil Trials: Some Tentative Views, 9 J. LAW & POL’Y 53, 65 (2000) (maintaining that while “each case is 
different,” generally, “where there is doubt, secrecy [orders in litigation] should be rejected”). 
 72. See Joseph S. Anderson, Hidden from the Public by Order of the Court: The Case Against 
Government-Enforced Secrecy, 55 S.C. L. REV. 711, 716–50 (2004) (discussing the actions taken in such 
cases by the judges of the U.S. District Court for the District of South Carolina). 
 73. Jack B. Weinstein & Catherine Wimberly, Secrecy in Law and Science, 23 CARDOZO L. REV. 1, 
11 (2001).  Judge Jack Weinstein is Senior Judge of the U.S. District Court for the Eastern District of 
New York and has presided over mass torts cases involving, among other toxins, asbestos, and agent 
orange. 
 74. Givelber & Robbins, supra note 67, at 136. 
 75. James W. Conrad, Jr., Open Secrets: The Widespread Availability of Information about the 
Health & Environmental Effects of Chemicals, 69 LAW & CONTEMP. PROBS. 141 (Summer 2006).  
Conrad is Assistant General Counsel of the American Chemistry Council, the trade association of U.S. 
chemical manufacturing companies. 
 76. 15 U.S.C. §§ 2601–2692 (2000). 
 77. 7 U.S.C. §§ 136–136y (2000). 
 78. Pub. L. No. 107-204, 116 Stat. 745 (2002) (codified as amended in scattered sections of 15 
U.S.C.). 
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civil liability—are adequate to ensure the full disclosure of relevant health and 
safety data.79 
Conrad enumerates and describes a variety of health, safety, and 
environmental laws that involve the production of information about chemical 
toxicity, but he does not evaluate the factors that encourage or discourage the 
disclosure of that information.80  For example, the classification of data 
submitted by chemical manufacturers to the U.S. Environmental Protection 
Agency (EPA) as “confidential business information” (CBI) provides a useful 
illustration of the gap between statute and practice.  In a recent evaluation of 
EPA ability to assess health risks and manage its chemical review program, the 
U.S. Government Accountability Office (GAO) found that chemical 
manufacturers make CBI claims in ninety-five percent of the new chemical 
premanufacture notices.81  The burden of evaluating the validity of all of these 
CBI claims falls on a resource-poor EPA, which rarely attempts to do so. 82 
Similarly, Conrad provides a useful listing of incentives for disclosure, 
including the effect of potential civil liability.  He acknowledges the important 
role of toxic tort suits in encouraging manufacturers “not only to act on risk 
information, but to affirmatively design products and services to minimize or 
avoid creating such risks in the first place.”  Missing from his discussion, though, 
are the disincentives—the factors that discourage transparency.  Returning to 
CBI, for example, there is in fact a strong incentive for chemical manufacturers 
to apply the CBI label in a most expansive manner, and little disincentive for 
them not to do so.83 
 
 79. Conrad, supra note 75, at 163. 
 80. Id. at 140–55. 
 81. U.S. GEN. ACCOUNTING OFFICE, REP. 05-458, CHEMICAL REGULATION: OPTIONS EXIST TO 
IMPROVE EPA’S ABILITY TO ASSESS HEALTH RISKS AND MANAGE ITS CHEMICAL REVIEW 
PROGRAM 5 (2005). 
TSCA generally prohibits disclosing to nonfederal officials trade secrets and privileged or 
confidential information protected under the Freedom of Information Act.  In addition, 
TSCA authorizes chemical companies to claim data as confidential business information.  
According to EPA officials, about 95 percent of the premanufacture notices for new chemicals 
submitted by chemical companies contain some information that is claimed as confidential. . . . 
While TSCA confidential business information can be provided to federal officials and 
contractors, it generally cannot be provided to other organizations responsible for assessing 
chemical risks, enforcing chemical control laws, and performing other environmental 
activities, including state regulatory agencies and foreign governments. 
 82. See id. (“While EPA has the authority to evaluate the appropriateness of confidentiality claims 
and can deny companies’ claims of confidentiality if they are found to be illegitimate, these efforts are 
time[-] and resource-intensive, and the agency does not have the resources to challenge a significant[ly] 
large number of claims.”). 
 83. See Wendy Wagner & David Michaels, Equal Treatment for Regulatory Science: Extending the 
Controls Governing the Quality of Public Research to Private Research, 30 AM. J.L. & MED. 119, 130 
(2004) (“Under most existing regulations, the CBI claims require no substantiation—a manufacturer 
has only to stamp the documents “confidential” for the privilege to apply.”).  In fact, no official from 
the company need take responsibility for asserting the claim; there are no penalties for asserting the 
claim when it is facially frivolous; and the firm is presumed to waive the privilege, or at least must 
justify it later, if they do not stamp this information as confidential when first submitting it to the 
agency.  Once the information is publicly disseminated, the company loses its right to claim 
misappropriation of a trade secret.  Based on this regulatory structure, firms openly concede that it is 
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Conrad also raises important concerns about the relationship of funding to 
the outcome of scientific studies.  In particular, he asserts that skepticism about 
the integrity of research, often focused on studies funded by industry, should be 
applied equally to studies that are funded by plaintiffs’ attorneys for use in 
litigation.84  He points out that conflict-of-interest concerns apply to all science 
whose sponsors have a financial interest in the outcome.85 
Indeed, there has been extensive discussion in the biomedical literature on 
this so-called funding effect, a term used to describe the correlation between the 
results of a study desired by a study’s sponsors and the reported results of that 
study.86  Several recent reviews have reported that pharmaceutical industry 
sponsorship was strongly associated with conclusions favorable to the sponsor.87  
Investigators have recently begun to explore whether a funding effect has 
tainted studies of the toxicity of industrial chemicals.88  Still, it is important to 
note that plaintiff attorneys sponsor little scientific research.  In contrast, the 
chemical industry currently employs thousands of scientists and supports a 
substantial proportion of the research in toxicology and related fields.  The 
sheer number of such studies and the magnitude of potential exposure to the 
 
more cost-effective for them to routinely stamp much internal information as CBI when no 
substantiation is required. 
Studies show that firms take full advantage of this generous approach to trade secrets and make the 
claim for information even when doing so is clearly without merit.  In 1990, for example, EPA reviewed 
CBI claims under the Toxic Substances Control Act and challenged some nonmeritorious claims.  By 
1992, “industry had voluntarily amended and withdrawn over 600 claims after EPA’s inquiries.”  CBI 
claims drop substantially (by as much as 50–60%) when EPA does require upfront substantiation of the 
nature of the trade secret protections, which it is legislatively required to do in other programs.  Id. at 
130–34. 
 84. Conrad, supra note 75, at 160–62. 
 85. Id. 
 86. SHELDON KRIMSKY, SCIENCE IN THE PRIVATE INTEREST: HAS THE LURE OF PROFITS 
CORRUPTED THE VIRTUE OF BIOMEDICAL RESEARCH? (2003). 
 87. J.E. Bekelman et al., Scope and Impact of Financial Conflicts of Interest in Biomedical 
Research: A Systematic Review, 289 JAMA 454, 454–65 (2003); Sheldon Krimsky, The Funding Effect in 
Science and its Implications for the Judiciary, 13 J. LAW & POL’Y 43 (2005); Joel Lexchin et al., 
Pharmaceutical Industry Sponsorship and Research Outcome and Quality, 326 BRIT. MED. J. 1167 
(2003); Richard Smith, Medical Journals are an Extension of the Marketing Arm of Pharmaceutical 
Companies, 2 PUB. LIBR. SCI. MED. 364, 364-66 (2005). 
 88. See F.S. Vom Saal & C. Hughes, An Extensive New Literature Concerning Low-dose Effects of 
Bisphenol A Shows the Need for a New Risk Assessment, 113 ENVTL. HEALTH PERSP. 926 (2005) 
(discussing a possible funding effect in research on low-dose exposure to bisphenol A (BPA), an 
environmental estrogen used in the manufacture of polycarbonate plastic, a resin widely used in food 
cans and dental sealants).  As recounted by the authors, exposure to BPA had been found in some 
studies to alter endocrine function at very low doses.  In response, the American Plastics Council hired 
the Harvard Center for Risk Analysis (HCRA) to conduct a “weight of the evidence” review of the 
toxicology; the HCRA panel reviewed nineteen animal studies and reported that it found no consistent 
affirmative evidence of low-dose BPA effects.  Id. 
This conclusion was challenged by government-funded scientists who felt that HCRA had chosen to 
examine only a minority of the forty-seven studies available at the time.  These scientists reviewed the 
115 published studies available in December 2004 and found results that differed markedly from the 
HCRA analysis.  They determined that ninety percent (94 of 104) of the studies paid for with 
government funds reported an effect associated with BPA exposure; however, not a single one of the 
eleven corporate-funded studies found an effect. 
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studied substances make it particularly important that these studies be available 
for public scrutiny and evaluation. 
In the final paper, Allen L. White explores the movement toward corporate 
transparency in the global economy.89  According to White, increased disclosure 
is driven by, among other factors, the international regime of “soft law,” 
comprised of dozens of codes, principles, standards, and guidelines whose 
implementation is dependent on voluntarism and moral persuasion, rather than 
legal enforceability.90  An important manifestation of this movement is the 
Global Reporting Initiative, in which more than six hundred major corporations 
issue annual “sustainability reports” encompassing environmental, social, and 
economic indicators.91 
White calls for global standards for corporate disclosure, arguing that higher 
standards of disclosure “build confidence and efficiency in capital markets” and 
contribute to the “quantity and quality of knowledge-based assets.”92  
Optimistically, he suggests that “public policies that drive higher standards of 
nonfinancial disclosure, especially those that relate to knowledge-based assets, 
are likely to yield a range of social benefits that have yet to achieve rigorous 
measurement and full disclosure.”93 
III 
A PROPOSAL: SARBANES-OXLEY FOR SCIENCE 
The questions discussed by these authors—namely, the costs and benefits 
associated with transparency in scientific research—are only a first step; as has 
been said many times, where you stand depends on where you sit.  There is only 
limited value in asking a beneficiary of a decision to evaluate its costs and 
benefits to others. 
Where does this leave us?  Although there is a basic societal preference for 
transparency and openness, there are situations and types of information that 
demand sequestration.  The tension is real and unavoidable.  There are no fast 
and easy rules for determining which data should be open and which held 
secret.  Indeed, it is very much determined by the situation.  The length of time 
information is held secret also depends on the situation; for example, the time 
needed to avoid giving competitors a technological advantage is likely to be far 
shorter than that necessary to protect national security. 
Since so much is open to interpretation and the stakes are so high, greater 
consideration needs to be given to the process that leads to information-
sequestration or disclosure.  The processes used to maintain secrecy are easily 
 
 89. Allen L. White, Why We Need Global Standards for Corporate Disclosure, 69 LAW & 
CONTEMP. PROBS. 167 (Summer 2006).  White is Vice President of the Tellus Institute and co-founder 
of the Global Reporting Initiative. 
 90. Id. at 167. 
 91. Id. at 175. 
 92. Id. 
 93. Id. 
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abused, and the institutional tools and imperatives that hide data are stronger 
than those that promote data sharing.  Rather than focus on the types of data 
that should be disclosed or sequestered, or on the processes and principles 
invoked to manage the disclosure and sequestration itself, I would like to begin 
the discussion with looking at new statutes that could be called “Sarbanes-
Oxley for Science.” 
When the Enron and WorldCom scandals were revealed, the executives of 
those firms claimed that they were unaware of the accounting 
misrepresentations in which their companies were engaged.94  The Sarbanes-
Oxley legislation was an attempt to ensure that the most senior managers of 
companies are held accountable for providing false or misleading financial data 
to regulators and to the public.95  The papers in this issue have identified a 
fundamental dilemma that in some ways parallels the concerns that led to 
Sarbanes-Oxley.  At present, there is virtually no oversight or independent 
review of corporate decisionmaking as it relates to the sequestration of 
scientific data.  An important lesson of the accounting scandals is that 
responsibility must be linked with accountability; this should apply to scientific 
as well as financial data. 
In the areas of public health and the environment, as long as the choice as to 
what scientific data are provided to regulators and the public rests in the hands 
of its corporate producers, it seems reasonable for the public to demand a 
modicum of accountability from those making the choices.  A Sarbanes-Oxley 
for Science would require corporations to designate a person responsible for 
reporting the results of studies undertaken by the firm.  He or she would have 
to certify that the information provided to the public and regulatory agencies, 
along with the methods used to obtain this information, was presented 
accurately and completely, and he or she would also be responsible for 
justifying designations of confidentiality.  The current Sarbanes-Oxley statute is 
sufficiently broad to protect whistleblowers who disclose certain types of 
scientific information,96 but the Sarbanes-Oxley for Science would further 
protect from discrimination those corporate epidemiologists, toxicologists, and 
other scientists who might choose to reveal information improperly hidden 
from regulators. 
Science, of course, is not accounting, and there are obvious limits to the 
application of accounting reporting requirements to the disclosure of scientific 
research findings.  For example, although conventions and guidelines for the 
application of certain scientific methods and techniques do exist, hypothesis-
 
 94. See Lisa M. Fairfax, Form Over Substance?: Officer Certification and Promise of Enhanced 
Personal Accountability under the Sarbanes-Oxley Act, 55 RUTGERS L. REV. 1, 12 (2002) (citing how 
several executives of Enron and WorldCom claimed to be unaware of their respective company’s 
wrongdoing). 
 95. Id. at 1–4. 
 96. Pub. L. No. 107-204, 116 Stat. 745 (2002) (codified as amended in scattered sections of 15 
U.S.C.).  See also Robert G. Vaughn, America’s First Comprehensive Statute Protecting Corporate 
Whistleblowers, 57 ADMIN. L. REV. 1 (2005). 
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driven science, in which creativity is highly valued, is less amenable to practice 
and reporting standards than the practice of accounting.  Beyond the actual 
conduct of studies, the scientific enterprise requires the interpretation of the 
results of these studies, and the synthesis of the results and interpretation of 
many studies.  Although science, like accounting, assumes the existence of an 
underlying truth, the policy shaped by science is driven by these interpretations 
and syntheses, rather than by the data themselves. 
The importance of ensuring that data interpretation is independent of 
conflicts of interest is tragically illustrated by the debate on the cardiovascular 
effects of Merck’s painkiller Vioxx (rofecoxib).  In early 2000, the results of a 
clinical trial showed that participants who took Vioxx for an average of nine 
months had a significantly higher risk of heart attack than those taking the 
comparison painkiller, naproxen (sold under the brand name Aleve).97  Since 
the comparison was between two biologically active products, scientists could 
have interpreted these results to mean either that Vioxx increased heart-attack 
risk or that naproxen reduced it.  Unfortunately, Merck’s researchers chose to 
promote the latter interpretation, ignoring other evidence that supported the 
former.98  Fortunately, among the clinical trials Merck had initiated was one in 
which Vioxx was compared to a placebo.99  When participants who took the 
drug for more than eighteen months suffered twice as many heart attacks and 
strokes as those taking the placebo, the trial was halted, and Vioxx was 
removed from the market.100  FDA scientists subsequently estimated that Vioxx 
was responsible for between 88,000 and 139,000 heart attacks—thirty to forty 
percent of which were probably fatal—in the five years the drug was on the 
market.101 
The raw data underlying study results are materials that should be 
considered in a Sarbanes-Oxley for Science initiative.  Although raw data from 
government-funded studies are generally available to private parties for 
inspection and re-analysis (enabling product defense experts to conduct post 
hoc analyses that challenge troubling findings), industry actors are under no 
similar obligation to release comparable raw data from their own studies.  
When private sponsors conduct research to influence public regulatory 
 
 97. Claire Bombardier et al., Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and 
Naproxen in Patients with Rheumatoid Arthritis, 343 N. ENG. J. MED. 1520, 1520 (2000). 
 98. See, e.g., Marvin A. Konstam et al., Cardiovascular Thrombotic Events in Controlled, Clinical 
Trials of Rofecoxib, 104 CIRCULATION 2280, 2280–88 (2001); Marvin A. Konstam & Laura A. 
Demopoulos, Letter to the Editor, Cardiovascular Events and COX-2 Inhibitors, 286 JAMA 2809 
(2001). 
 99. Merck conducted a trial to determine if Vioxx inhibited the development of colon polyps; since 
there are no other treatments that accomplish this, the study compared Vioxx with a placebo. 
 100. Press Release, Food and Drug Administration, FDA Issues Public Health Advisory on Vioxx 
as its Manufacturer Voluntarily Withdraws the Product (Sept. 30, 2004) available at 
http://www.fda.gov/bbs/topics/news/2004/NEW01122.html; see also Robert S. Bresalier, Robert S. 
Sandler, Hui Quan, et. al., Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma 
Chemoprevention Trial, 352 N. ENG. J. MED. 1092 (2005). 
 101. FDA, Merk and Vioxx: Putting Patient Safety First?: Hearing before the S. Comm. on Finance, 
108th Cong. 1 (2004) (statement of David J. Graham, MD, MPH). 
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proceedings, these studies should be subject to the same access and reporting 
provisions as those applied to publicly funded science.  Public health is not well 
served by the unequal treatment of public and private science.102 
Independent processes and procedures—such as those that would be 
included in a Sarbanes-Oxley for Science—are needed to dictate the decisions 
to sequester or disclose scientific information, as well as to ensure 
accountability to the public of those who make such decisions.  In the public 
sector, FOIA and FACA facilitate openness in decisionmaking, and these two 
valuable statutes need re-invigoration.  For the private sector, additional 
accountability for those who make decisions around openness and sequestration 
would contribute to greater transparency and improved protection for the 
public health and environment. 
IV 
CONCLUSION 
Data sequestration serves many functions, including protecting national 
security, investment value, and individual confidentiality.  But it comes with 
societal costs, particularly around protecting the public health and environment, 
and excessive secrecy may damage the scientific enterprise itself. 
The symposium papers in this issue tell us that, most basically, openness 
needs to be seen not as a simple characteristic of the scientific process, but as a 
dynamic process, in and of itself.  Institutional structures and procedures must 
be built into a range of legal and regulatory activities so that all users of the 
results of scientific investigations—scientists and corporations, regulators and 
jurists, legislators and reporters—would be regularly required to ask and be 
asked if their actions sequestering data are truly necessary.  Further, these users 
would have to consider whether the benefits that accrued from hiding the data 
outweighed those associated with openness—while also considering the fairness 
and impact of the ways in which those benefits are distributed. 
The tension between openness and sequestration in science is not new, 
although we are at a point at which this conflict feels particularly acute, and the 
stakes seem particularly high.  Secrecy is often the easier road, and 
transparency is not now, and perhaps never has been, the default position.  We 
have learned from the debate reflected in these pages that it is exceedingly 
difficult to categorize in the abstract what types of data should be kept 
confidential and what should be released, and to whom.  Sheila Jasanoff’s words 
from this issue bear repeating: “[T]he degree of openness is context-specific and 
needs to be traded off against other important social values.  The problem for 
contemporary law and policy is to develop principled approaches to 
 
 102. See Wendy Wagner & David Michaels, Equal Treatment for Regulatory Science: Extending the 
Controls Governing the Quality of Public Research to Private Research, 30 AM. J.L. & MED. 119 (2004). 
01__FOREWORD.DOC 10/4/2006  9:00 AM 
Summer 2006] FOREWORD 19 
maintaining the desired balance.”103  The articles in this issue should contribute 
significantly to the continued pursuit of that balance. 
 
 103. Jasanoff, supra note 12, at 22. 
